Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 11/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913220 | 1.00 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL17377651 | 1.00 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL4008546 | 0.98 | KIF11 (0.57) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL913478 | 0.92 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL4012213 | 0.84 | KIF11 (0.63) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL8714858 | 0.81 | KIF11 (0.52) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL25077100 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR | |
| SCHEMBL5820308 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR | |
| SCHEMBL21411547 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR | |
| SCHEMBL25077435 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109906230-B | Endosomolytic agent for gene therapy | UCB生物制药有限责任公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3519423-B1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB Biopharma SRL (BE) | 2021-04-07 | — | — | EP | disclosed |
| US-10842884-B2 | Endosomolytic agents for gene therapy | UCB Biopharma SRL (BE) | 2020-11-24 | — | — | US | disclosed |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | UCB BIOPHARMA SRL (UCB BIOPHARMA SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2019-10-03 | — | — | US | disclosed |
| CN-109906230-A | Endosomolytic agent for gene therapy | UCB生物制药私人有限公司 | 2019-06-18 | — | — | CN | disclosed |
| WO-2018060280-A1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB BIOPHARMA SPRL (BE) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842884-B2 | Endosomolytic agents for gene therapy | YARS1, ARSA, RPS6 | KIF11 1976/4885HRH4 1596/4885TK2 408/4885 |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | YARS1, ARSA, RPS6 | KIF11 1976/4885HRH4 1596/4885TK2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.